Vivo Capital, a healthcare investment firm, announced the final closing of Vivo 
Capital Fund IX, L.P. (the "Fund") at $1.43 billion in committed capital from a 
broad group of existing and new global institutional investors. The firm plans 
to use these funds to invest in and build innovative and rapidly growing 
healthcare and life science companies. Vivo Capital believes its unique global 
capabilities enable the firm to help companies develop and commercialize new 
therapies and products in markets around the world. Since its inception in 
1996, the firm has raised over $4 billion in capital and backed over 200 
private and public portfolio companies.

Logo - https://mma.prnewswire.com/media/1019830/Vivo_Logo.jpg

About Vivo Capital
Founded in 1996, Vivo Capital is a healthcare investment firm focused on 
investing in and building high quality companies around the world. Vivo Capital 
employs a distinctive multi-pronged strategy of identifying and working with 
companies that are developing and commercializing products and technology. Vivo 
Capital (http://www.vivocapital.com/) is headquartered in Palo Alto, with 
offices in Beijing, Shanghai, Hong Kong, and Taipei.


SOURCE: Vivo Capital

CONTACT: Zhanping Wu, General Counsel, Vivo Capital, (650) 688-0818